WHO recommendation on umbilical vein injection of oxytocin for the treatment of retained placenta
Efforts to prevent and reduce morbidity and mortality due to PPH (Postpartum haemorrhage) can help to address the profound inequities in maternal and perinatal health globally. To achieve this, skilled health personnel, health managers, policy-makers and other stakeholders need up-to-date and eviden...
| Corporate Authors: | , , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Geneva, Switzerland
World Health Organization
[2020], 2020
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Efforts to prevent and reduce morbidity and mortality due to PPH (Postpartum haemorrhage) can help to address the profound inequities in maternal and perinatal health globally. To achieve this, skilled health personnel, health managers, policy-makers and other stakeholders need up-to-date and evidence-informed recommendations to guide clinical policies and practices. In 2019, the Executive Guideline Steering Group (GSG) for the World Health Organization (WHO) maternal and perinatal health recommendations prioritized updating of the existing WHO recommendation: Umbilical vein injection of oxytocin for the treatment of retained placenta, in response to the availability of new evidence. The recommendation in this document thus supersedes the previous WHO recommendations on "intraumbilical vein injection of oxytocin for treatment of retained placenta" as published in the 2012 guideline, WHO recommendations for the prevention and treatment of postpartum haemorrhage |
|---|---|
| Item Description: | Replacement of WHO recommendations for the prevention and treatment of postpartum haemorrhage, [2012] |
| Physical Description: | 1 PDF file (viii, 57 pages) |
| ISBN: | 9789240013957 9789240013940 |